Trial
NCT05904496
A Study of BGB-30813 Alone or in Combination With Tislelizumab in Participants With Advanced or Metastatic Solid Tumors
Phase ITERMINATEDSAFETYConfidence: MEDIUM
Sponsor
BeiGene
Collaborators
—
Condition
Advanced Solid Tumors
Intervention
BGB-30813
Why stopped
The Sponsor has made the decision to discontinue the clinical development of BGB-30813 and close the study based on imbalanced benefit/risk profile in the BGB-A317-30813-101 study.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-09-16